Ceftriaxone Kabi, 1 g 10 pcs

Pharmacotherapeutic group: Antibiotic-cephalosporin

ATC code: J01DD04

Pharmacodynamics:

A broad spectrum III generation cephalosporin antibiotic for parenteral administration. Bactericidal activity is caused by inhibition of bacterial cell wall synthesis. It is characterized by resistance to action of most beta-lactamases of gram-negative and gram-positive microorganisms.

Active against the following microorganisms: Gram-positive aerobes -Staphylococcus aureus (including strains producing penicillinase) Staphylococcus epidermidis Streptococcus pneumoniae Streptococcus pyogenes Streptococcus spp. viridans; Gram-negative aerobes: Acinetobacter calcoaceticus Enterobacter aerogenes Enterobacter cloacae Escherichia coli Haemophilus influenzae (including penicillinase-producing strains) Haemophilus parainfluenzae Klebsiella spp. Klebsiella pneumoniae) Moraxella catarrhalis (including penicillinase-producing strains) Morganella morganii Neisseria gonorrhoeae (including penicillinase-producing strains) Neisseria meningitidis Proteus mirabilis Proteus vulgaris Serratia spp. (including Serratia marcescens) Borrelia burgdorferi; some strains of Pseudomonas aeruginosa are also sensitive; anaerobes: Bacteroides fragilis Clostridium spp. (except Clostridium difficile) Peptostreptococcus spp.

Has in vitro activity against most strains of the following microorganisms although the clinical significance of this is unknown: Citrobacter diversus Citrobacter freundii Providencia spp. Providencia rettgeri Salmonella spp. (including Salmonella typhi) Shigella spp.; Streptococcus agalactiae Bacteroides bivius Bacteroides melaninogenicus.

Methicillin resistant staphylococci are also resistant to cephalosporins including ceftriaxone many strains of group D streptococci and enterocococci including enterocococci.Enterococcus faecalis are also resistant to ceftriaxone.

Pharmacokinetics:

Bioavailability – 100% time of reaching maximum concentration after intravenous administration – at the end of infusion. Maximal concentration in 2 g dose is about 257 mcg/ml. In adults, 2-24 hours after administration at a dose of 50 mg/kg, the concentration in the cerebrospinal fluid (CSF) is many times higher than the minimum suppressive concentration (MSC) for the most common meningitis pathogens. It penetrates well into the CSF during cerebral membrane inflammation. Binding with plasma proteins is 83-96 %. Distribution volume – 012-014 l/kg (578-135 l) in children – 03 l/kg plasma clearance – 058-145 l/h renal 032-073 l/h.

Indications

Active ingredient

Composition

How to take, the dosage

Interaction

Special Instructions

Contraindications

Side effects

Allergic reactions: rash itching fever or chills.

Local reactions: when administered intravenously – phlebitis soreness along the vein.

Central nervous system: headache dizziness.

Acts of the sexual system: vaginal candidiasis vaginitis.

Digestive system: diarrhea nausea vomiting taste disorder pseudomembranous colitis.

Hematopoietic disorders: anemia (including hemolytic) leukopenia lymphopenia neutropenia thrombocytopenia thrombocytosis eosinophilia.

Laboratory measures: increase (decrease) of prothrombin time hematuria increase of “hepatic” transaminases and alkaline phosphatase (ALP) activity hyperbilirubinemia hypercreatininemia increase of urea concentration presence of urine sediment.

Others: increased sweating “hot flashes” of blood.

Unwanted reactions with an incidence of less than 01%: abdominal pain agranulocytosis allergic pneumonitis anaphylaxis basophilia cholelithiasis bronchospasm colitis dyspepsia nasal bleeding abdominal bloating “sludge phenomenon” gallbladder glucosuria hematuria jaundice leukocytosis lymphocytosis monocytosis nephrolithiasis feeling heart palpitations cramps serum disease stomatitis glossitis oliguria allergic dermatitis urticaria edema multiform erythema Stevens-Johnson syndrome Lyell syndrome.

Overdose

Pregnancy use